VIP Peptide: A Research Overview of Vasoactive Intestinal Peptide, Its Structure and VPAC Receptors
Vasoactive intestinal peptide, usually shortened to VIP peptide, is one of the most studied neuropeptides in the secretin/glucagon family. It has been the subject of research for more than five decades, across gut, nervous system, vascular and immune models. This overview summarizes where VIP came from, its structure, the receptors it acts on, the main areas of published research, and practical handling notes for laboratories. It is a research summary only: VIP sold by Pure Tested Peptides is for laboratory research use and is not for human or veterinary use.
Discovery
VIP was first isolated by Sami Said and Viktor Mutt from porcine small intestine and described in 1970 as a polypeptide with broad biological activity, including effects on blood vessels in animal preparations (Said & Mutt, Science, 1970). Its full amino acid sequence was reported a few years later (Mutt & Said, Eur J Biochem, 1974), and chemical synthesis of the peptide was published the same year (Bodanszky et al., J Am Chem Soc, 1974).
Structure
VIP is a 28-amino-acid peptide with an amidated C-terminus. The commonly cited human sequence is:
HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2
Its molecular weight is roughly 3.3 kDa. VIP belongs to the secretin/glucagon superfamily and is closely related to pituitary adenylate cyclase-activating polypeptide (PACAP), with which it shares substantial sequence similarity and overlapping receptors. Two structural features matter in the lab: the methionine at position 17 can oxidize, and the peptide’s many basic residues (lysines and arginines) influence solubility and surface adsorption.
Receptors: VPAC1, VPAC2 and PAC1
VIP acts mainly through two class B G protein-coupled receptors, VPAC1 and VPAC2, which it shares with PACAP. A third receptor, PAC1, binds PACAP with much higher affinity than VIP. Activation of VPAC receptors is classically linked to Gs coupling and increased intracellular cAMP, although other signaling routes have been described. The receptor family is reviewed in detail in the IUPHAR review by Harmar et al. (Br J Pharmacol, 2012) and by Dickson & Finlayson (Pharmacol Ther, 2009). Structural and molecular pharmacology of VPAC receptors is covered by Couvineau & Laburthe (Br J Pharmacol, 2012).
For researchers, this receptor sharing is the main design challenge. An effect seen after adding VIP to a cell or tissue preparation could, in principle, involve VPAC1, VPAC2 or both, and PACAP present in the same system may act on the same receptors. Published work therefore often pairs VIP with receptor-selective agonists or antagonists, receptor knockout models, or cell lines expressing a single receptor subtype.
Main areas of published research
Gastrointestinal and smooth muscle models
Given its origin, much early work examined VIP in intestinal tissue, where it is found in enteric neurons and has been studied in relation to smooth muscle tone and epithelial secretion in experimental preparations.
Vascular models
The “vasoactive” in VIP’s name comes from the vasodilator activity seen in its original animal experiments, and vascular smooth muscle remains a common research setting.
Nervous system and circadian research
VIP is expressed widely in central and peripheral neurons. In neuroscience research it is often discussed in connection with the suprachiasmatic nucleus, where VIP-expressing neurons are studied as part of circadian timing networks.
Immune research
A substantial literature examines VIP as a neuropeptide that interacts with immune cells expressing VPAC receptors. Delgado & Ganea (Amino Acids, 2013) review this immunological research.
These summaries describe what has been studied, not established outcomes for any use. Results from cell or animal models should not be read as evidence of effects in people.
Key facts at a glance
| Property | Detail |
|---|---|
| Full name | Vasoactive intestinal peptide |
| Length | 28 amino acids, C-terminal amide |
| Approximate molecular weight | About 3.3 kDa |
| Peptide family | Secretin/glucagon superfamily, related to PACAP |
| Main receptors | VPAC1 and VPAC2 (class B GPCRs) |
| First described | 1970, isolated from porcine small intestine |
These are reference details for planning experiments and checking documentation. Always confirm the exact sequence, salt form and fill amount for the lot you receive against its Certificate of Analysis.
Research considerations
- Short stability in biological matrices: VIP is known to be degraded quickly by peptidases in biological fluids, which is relevant to sampling and time-course design.
- Receptor overlap: because VIP and PACAP share VPAC receptors, receptor-selective tools and appropriate controls help with interpretation.
- Oxidation: Met17 oxidation can be detected as a +16 Da shift by mass spectrometry, so identity data on the COA is useful when comparing lots.
- Adsorption: basic peptides can stick to some plastics and glass; low-binding consumables are often preferred for dilute solutions.
Handling and documentation
Lyophilized VIP is generally stored cold, dry and protected from light, then reconstituted according to the lab’s protocol. Once in solution, single-use aliquots help limit freeze-thaw cycles. For general storage practice, see our peptide storage and stability checklist. Each lot should be matched to its Certificate of Analysis with identity and purity data, as described on our quality control and purity testing page.
Our VIP 10mg research peptide is listed in our research peptide shop. For another short-sequence compound overview in the same format, see our KPV peptide research overview.
Frequently Asked Questions
What is VIP peptide?
VIP, or vasoactive intestinal peptide, is a 28-amino-acid neuropeptide in the secretin/glucagon family. It was first isolated from porcine small intestine by Said and Mutt in 1970.
Which receptors does VIP bind?
VIP acts mainly through VPAC1 and VPAC2, class B G protein-coupled receptors it shares with PACAP. The PAC1 receptor binds PACAP with much higher affinity than VIP.
How is VIP related to PACAP?
VIP and PACAP are structurally related peptides in the same superfamily and share VPAC1 and VPAC2 receptors. Researchers often use selective tools and controls to separate their effects.
What should a VIP COA show?
A useful COA shows identity by mass spectrometry, purity by HPLC, the lot number and test date. Mass data can also help detect methionine oxidation, which appears as a +16 Da shift.
Is VIP from Pure Tested Peptides for human use?
No. VIP sold by Pure Tested Peptides is for laboratory research use only and is not for human or veterinary use.
Research use only. All Pure Tested Peptides products are sold strictly for laboratory research and are not for human or veterinary use. Nothing in this article is medical advice or a claim that any compound diagnoses, treats, cures, or prevents any condition.




Leave a Reply
Want to join the discussion?Feel free to contribute!